| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023313373 |
| P356 | DOI | 10.1186/1475-2867-13-21 |
| P932 | PMC publication ID | 3599506 |
| P698 | PubMed publication ID | 23497288 |
| P5875 | ResearchGate publication ID | 236051722 |
| P2093 | author name string | Yoshihiro Matsumoto | |
| Yusuke Takahashi | |||
| Yoshinao Oda | |||
| Yukihide Iwamoto | |||
| Jun-Ichi Fukushi | |||
| Satoshi Kamura | |||
| Toshifumi Fujiwara | |||
| Keiichiro Iida | |||
| Mihoko Hatano | |||
| Akira Nabashima | |||
| Yuko Fujiwara-Okada | |||
| P2860 | cites work | A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment | Q24310207 |
| MicroRNA gene expression deregulation in human breast cancer | Q27860690 | ||
| Oncomirs - microRNAs with a role in cancer | Q27860773 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture | Q28245251 | ||
| miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells | Q28278471 | ||
| Diagnosis and treatment of Ewing's sarcoma | Q28286292 | ||
| Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells | Q33289523 | ||
| CD133 expression in chemo-resistant Ewing sarcoma cells | Q33546702 | ||
| MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. | Q33967256 | ||
| MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo | Q34039589 | ||
| Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway | Q34059738 | ||
| MicroRNA miR-125a controls hematopoietic stem cell number | Q34069509 | ||
| Negative regulation of the tumor suppressor p53 gene by microRNAs. | Q34142778 | ||
| Mutations that lead to reiterations in the cell lineages of C. elegans | Q34282331 | ||
| Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. | Q34312488 | ||
| Macrophage infiltration predicts a poor prognosis for human ewing sarcoma | Q35168030 | ||
| An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells | Q36288990 | ||
| EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma | Q37135628 | ||
| Tumor resistance to apoptosis | Q37323744 | ||
| MicroRNA and drug resistance | Q37751868 | ||
| Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? | Q37856115 | ||
| Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors | Q38346476 | ||
| Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples | Q38430803 | ||
| miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells | Q39433259 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. | Q39569218 | ||
| MicroRNA miR-125b is a prognostic marker in human colorectal cancer | Q39576859 | ||
| miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes | Q39649207 | ||
| miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines | Q39738386 | ||
| MicroRNA-125b is a novel negative regulator of p53. | Q39871732 | ||
| Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma | Q39958103 | ||
| Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b | Q40207487 | ||
| Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. | Q40427655 | ||
| Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. | Q40458621 | ||
| Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. | Q40593401 | ||
| Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. | Q40707005 | ||
| Activation of Bak, Bax, and BH3-only proteins in the apoptotic response to doxorubicin. | Q40709009 | ||
| High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. | Q43626751 | ||
| Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone | Q44320806 | ||
| C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. | Q44438546 | ||
| Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. | Q44830954 | ||
| Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study | Q44978596 | ||
| Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. | Q46434393 | ||
| Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells | Q46623147 | ||
| Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. | Q50751924 | ||
| Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. | Q53332426 | ||
| The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells. | Q53530281 | ||
| Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways. | Q54328681 | ||
| CD99 engagement: an effective therapeutic strategy for Ewing tumors | Q57009385 | ||
| Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells | Q72090449 | ||
| Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999 | Q77783931 | ||
| Ewing's sarcoma | Q82884131 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 21 | |
| P577 | publication date | 2013-03-04 | |
| P1433 | published in | Cancer Cell International | Q1829859 |
| P1476 | title | miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor | |
| P478 | volume | 13 |
| Q61815612 | Bromodomain‑containing protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein |
| Q38861998 | Cadherin-11 regulates the metastasis of Ewing sarcoma cells to bone. |
| Q52629167 | Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells. |
| Q35987417 | Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine |
| Q36386088 | FARE-CAFE: a database of functional and regulatory elements of cancer-associated fusion events |
| Q33739269 | Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor |
| Q38546133 | Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. |
| Q36687760 | Mechanisms of doxorubicin resistance in hepatocellular carcinoma |
| Q50093882 | MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1β. |
| Q35550226 | MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells |
| Q59336829 | MicroRNA Regulation of Energy Metabolism to Induce Chemoresistance in Cancers |
| Q38296481 | MicroRNA expression and its clinical implications in Ewing's sarcoma |
| Q35217304 | MicroRNA profiling in intraocular medulloepitheliomas |
| Q28083277 | MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown |
| Q33914573 | MicroRNAs: novel players in cancer diagnosis and therapies. |
| Q35673637 | MicroRNAs: short non-coding players in cancer chemoresistance. |
| Q41924654 | Noncoding RNA in drug resistant sarcoma |
| Q26773316 | Oncogenic MicroRNAs: Key Players in Malignant Transformation |
| Q37587311 | Regulation of multidrug resistance by microRNAs in anti-cancer therapy |
| Q33850064 | Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators |
| Q92713862 | Signatures of circulating microRNA in four sarcoma subtypes |
| Q26765247 | The Landscape of Pancreatic Cancer Therapeutic Resistance Mechanisms |
| Q58694197 | The Network of Non-coding RNAs in Cancer Drug Resistance |
| Q38437281 | The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy. |
| Q38182423 | Therapy resistance mechanisms in Ewing's sarcoma family tumors |
| Q42275473 | Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways |
| Q26782649 | Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward? |
| Q26829949 | Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression |
| Q26800124 | What Do We Know about the Role of miRNAs in Pediatric Sarcoma? |
| Q42142854 | miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling |
| Q61760942 | miRNA-Targeted Therapies in the Most Prevalent Pediatric Solid Tumors |
Search more.